EMPOWER-Lung 3 results in NSCLC patients with PD-L1 ≥1%
Dr Ana Baramidze, clinical researcher at the Todua Clinic in Tbilisi, Georgia described the outcomes of the EMPOWER-Lung 3 study, evaluating cemiplimab + chemotherapy in NSCLC patients with PD-L1 expression ≥1%.
You may also be interested in:
With the educational support of:
 |
 |
 |
 |
 |